Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
NCT Number:
NCT02723994
Phase:
II
Protocol Type:
Treatment
Age Group:
Children
Disease Sites:
Lymphoid Leukemia
Study Objectives:
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Study Documents
(MUSC NetID required for document access)